Skip to main content
. 2022 Mar 18;129(5-6):689–701. doi: 10.1007/s00702-022-02485-6

Table 2.

Risperidone daily doses and serum concentrations in different subsample

Patients (N) Risperidone daily dose
Mean ± SD median,
(IQR) (mg/day)		 Concentration RISam (active moiety)
Mean ± SD median, (IQR) (ng/ml)		 Concentration RIS
Mean ± SD median, (IQR) (ng/ml)		 Concentration 9-OH-RIS
Mean ± SD median, (IQR) (ng/ml)		 Correlation daily dose RISam concentration
(rs,,p)		 Group differences in RISam concentrations (p)
All (64)

3.9 ± 1.9

4.0

(2.0–5.4)

32.2 ± 22.1

27.5

(17.0–43.8)

8.6 ± 11.1,

3.5

(2.0–12.0)

23.7 ± 16.8,

20.5

(12.2–30.0)

0.49,

 <0.001

 graphic file with name 702_2022_2485_Figa_HTML.gif
Boys (45)

4.0 ± 2.0

4.0

(2.0–5.5)

23.1 ± 21.1

28.0

(17.0–43.5)

9.2 ± 11.1

4.0

(2.0–15.5)

22.6 ± 15.8

20.0

(11.5–30.0)

0.59,

 <0.001

 0.97
Girls (19)

3.6 ± 1.5

3.0

(2.5–4.5)

33.4 ± 24.8

26.0

(16.0–44.0)

7.1 ± 11.2

3.0

(2.0–9.0)

26.3 ± 19.3

23.0

(13.0–31.0)

0.27,

0.26
Mono-therapy (13)

4.2 ± 1.5

4.5

(3.0–5.8)

22.2 ± 8.4

24.0

(17.0–29.0)

3.8 ± 4.3

3.0

(1.54.0)

18.5 ± 8.5

20.0

(10.6–26.0)

0.37,

0.21

graphic file with name 702_2022_2485_Figb_HTML.gif

0.10
Co-medication (50)

3.7 ± 1.9

3.5

(2.0–5.0)

34.9 ± 24.0

30.0

(15.8–44.0)

10.0 ± 12.0

4.0

(2.0–13.3)

25.0 ± 18.4

21.0

(12.8–33.0)

0.56,

 <0.001

Responders

(43)

3.8 ± 2.0

4.0

(2.0–5.0)

31.9 ± 23.3

26.0

(16.0–43.0)

7.8 ± 9.9

3.0

(3.0–13.0)

24.4 ± 17.9

20.5

(12.0–31.0)

0.57

 <0.001

 graphic file with name 702_2022_2485_Figc_HTML.gif

Non-Responders

(16)

4.0 ± 1.8

4.5

(3.0–5.5)

33.8 ± 21.3

29.0

(17.0–44.0)

9.7 ± 14.1

3.5

(2.0–9.0)

24.2 ± 17.1

20.5

(11.8–29.5)

0.19

0.49

 0.77

RISam (active moiety) = sum concentration of risperidone (RIS) and its active metabolite 9-OH-risperidone (9-OH-RIS).